

FOI 3089

19th May 2025

FREEDOM OF INFORMATION ACT 2000 – INFORMATION REQUEST

How many patients were treated in the last 3 months by the Dermatology department (for any medical condition) with the following biologic drugs:

Response:

Current patients as of 07/05/25

Adalimumab – Humira	33
Adalimumab Biosimilar	315
Apremilast	0
Bimekizumab	16
Brodalumab	6
Certolizumab	5
Deucravacitinib	0
Dimethyl fumarate	0
Etanercept – Enbrel	0
Etanercept Biosimilar	2
Guselkumab	64
Infliximab – Remicade	0
Infliximab Biosimilar	10
Ixekizumab	115
Risankizumab	93
Secukinumab	44
Tildrakizumab	5
Ustekinumab – Stelara	2
Ustekinumab Biosimilar	23
Omalizumab	37
Spesolimab	0

How many patients were treated in the last 3 months by the Dermatology department for HS (Hidradenitis Suppurativa) ONLY with the following:

Response:

Current patients as of 07/05/25

Adalimumab – Humira	22
Adalimumab Biosimilar	53
Bimekizumab	1
Certolizumab	0
Infliximab – Remicade	0
Infliximab Biosimilar	7
Secukinumab	13
Ustekinumab – Stelara	0
Ustekinumab Biosimilar	0

Email: Foi.Team@Southerntrust.hscni.net